Amiodarone: Clinical Management Guide
FDA-Approved Indication and Off-Label Use
Amiodarone is FDA-approved exclusively for life-threatening ventricular arrhythmias, but is widely used off-label for atrial fibrillation, particularly in patients with structural heart disease. 1
The drug is recommended as the antiarrhythmic agent of choice for patients who have survived sustained ventricular tachyarrhythmias, especially those with left ventricular dysfunction 1. For atrial fibrillation, amiodarone functions as a second-line agent in patients with structural heart disease or highly symptomatic patients without heart disease 1.
Key Clinical Context
- ICDs are superior to amiodarone for reducing mortality in high-risk patients with previous myocardial infarction; amiodarone should be used as adjunctive therapy to reduce ICD shocks or control atrial fibrillation in selected patients 1
- For relatively asymptomatic atrial fibrillation patients on anticoagulation, rate-control strategies are preferred over rhythm control with amiodarone due to toxicity concerns and lack of outcome improvement 1
Dosing Regimens
Intravenous Administration (Acute Setting)
For life-threatening arrhythmias: 1, 2
- Loading: 150 mg IV bolus over 10 minutes (may repeat in 10-30 minutes if needed)
- Maintenance: 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours
- Supplemental boluses: 150 mg in 100 mL D5W over 10 minutes for breakthrough VF or hemodynamically unstable VT
- Maximum initial infusion rate: 30 mg/min
- Concentration limits: ≤2 mg/mL for peripheral IV (>1 hour infusions); higher concentrations require central venous catheter
Critical administration requirements: 2
- Must use volumetric infusion pump (not drop counters—can underdose by 30%)
- Administer through dedicated central venous catheter when possible
- Use in-line filter
- Use glass or polyolefin bottles (not evacuated glass containers)
- Infusions >2 hours must be in glass or polyolefin bottles with D5W
Oral Administration (Long-term)
For ventricular arrhythmias: 1
- Loading: 800-1,600 mg/day in divided doses until 10 g total administered
- Maintenance: 200-400 mg/day
For atrial fibrillation: 1
- Loading: 600-800 mg/day in divided doses until 10 g total administered
- Maintenance: 200 mg/day
Transition from IV to oral: 1
- <1 week IV: 800-1,600 mg/day oral
- 1-3 weeks IV: 600-800 mg/day oral
3 weeks IV: 400 mg/day oral
Dosing Principles
Keep amiodarone at the lowest effective dose to minimize toxicity 1. Modern practice favors maintenance doses of 100-200 mg/day, with doses ≥300 mg/day generally obsolete 3.
Monitoring Requirements
Baseline Assessment
- Thyroid function tests (TSH, free T4)
- Liver function tests (AST, ALT)
- Pulmonary function tests with diffusing capacity
- Chest radiograph
- Ophthalmologic examination
- ECG (baseline QT interval)
Ongoing Surveillance
Laboratory monitoring at minimum every 6 months: 1
- Liver function tests
- Thyroid function tests
- Assess for pulmonary symptoms (cough, progressive dyspnea) at each visit
- Monitor for bradycardia, QT prolongation
- Chest radiograph if pulmonary symptoms develop
- Annual ophthalmologic examination for corneal deposits
Drug Interaction Monitoring
Digoxin: 2
- Increases serum digoxin by 70% after one day
- Reduce digoxin dose by approximately 50% or discontinue
- Monitor serum levels closely
Warfarin: 2
- Increases prothrombin time by 100% after 3-4 days
- Reduce warfarin dose by one-third to one-half
- Monitor INR closely; effects peak at 7 weeks 1
Other antiarrhythmics: 2
- Quinidine: Reduce dose by one-third (increases quinidine levels by 33%)
- Procainamide: Reduce dose by one-third (increases levels by 55%)
- Flecainide: Adjust dose downward
Statins: 2
- Avoid simvastatin (risk of rhabdomyolysis via CYP3A4 inhibition)
- Use alternative statin or lowest effective dose
Major Adverse Effects and Management
Pulmonary Toxicity (Most Serious)
Presentation: Subacute cough and progressive dyspnea with patchy interstitial infiltrates on chest radiograph; reduced diffusing capacity on PFTs 1
Management:
- Discontinue amiodarone immediately if pulmonary toxicity suspected
- Obtain chest CT, pulmonary function tests
- Consider pulmonology consultation
- Corticosteroids may be required
Thyroid Dysfunction (15-20% incidence) 6, 7
Amiodarone-induced hypothyroidism (AIH):
- Manage with levothyroxine
- Do not routinely discontinue amiodarone 6
Amiodarone-induced thyrotoxicosis (AIT):
- Requires phenotypic differentiation 6, 7
- Type 1 AIT: Antithyroid drugs (methimazole)
- Type 2 AIT: Corticosteroids preferred
- Consider thyroidectomy if cardiac status deteriorating and amiodarone continuation necessary 7
- Endocrinology consultation recommended
Hepatotoxicity
- Monitor transaminases every 6 months 1
- Discontinue if persistent elevation >3× upper limit of normal
- Warning: High-concentration/high-rate IV loading can cause hepatocellular necrosis and acute renal failure leading to death 2
Bradycardia and Conduction Abnormalities
- May require pacemaker insertion in severe cases 2
- Use caution with beta-blockers and calcium channel blockers 2
Ocular Effects
- Corneal microdeposits (common, usually asymptomatic)
- Annual ophthalmologic examination recommended
Contraindications and Precautions
Absolute Contraindications
- Severe sinus node dysfunction causing marked sinus bradycardia
- Second- or third-degree AV block (without pacemaker)
- Cardiogenic shock
- Known hypersensitivity to amiodarone or iodine
Relative Contraindications/Cautions
- Pregnancy and breastfeeding (crosses placenta, present in breast milk) 1
- Concomitant use with drugs prolonging QT interval (fluoroquinolones, macrolides, azoles) 2
- Baseline QT prolongation
- Electrolyte abnormalities (hypokalemia, hypomagnesemia)
Drug Interactions Requiring Dose Adjustment or Avoidance
Avoid or use extreme caution: 2
- Simvastatin (rhabdomyolysis risk)
- St. John's Wort (reduces amiodarone levels via CYP3A4 induction)
- Rifampin (reduces amiodarone efficacy)
Requires dose reduction: 2
- Warfarin (reduce by 1/3 to 1/2)
- Digoxin (reduce by ~50%)
- Quinidine, procainamide (reduce by 1/3)
- Cyclosporine (monitor levels closely)
Alternative Therapies
For Ventricular Arrhythmias
- Implantable cardioverter-defibrillator (ICD): Superior to amiodarone for mortality reduction in high-risk patients 1
- Sotalol (less effective than amiodarone but fewer extracardiac side effects)
- Catheter ablation for specific arrhythmias
For Atrial Fibrillation
- Rate control strategy: Preferred for relatively asymptomatic patients 1
- Beta-blockers
- Calcium channel blockers (diltiazem, verapamil)
- Digoxin
- Rhythm control alternatives:
- Sotalol or propafenone (amiodarone maintains sinus rhythm in 65% vs 37% at 16 months, NNT 3.6) 1
- Dofetilide
- Catheter ablation (increasingly first-line for symptomatic paroxysmal AF)
Clinical Pearls and Pitfalls
Pharmacokinetics
- Elimination half-life averages 58 days due to lipid storage 1
- Bioavailability is poor (22-95%); enhanced when taken with food 1
- Effects of drug interactions (digoxin, warfarin) do not peak until 7 weeks after initiation 1
- Grapefruit juice inhibits metabolism and increases levels 1
Common Pitfalls
- Using maintenance doses >300 mg/day (increases toxicity without added benefit) 3
- Failing to reduce doses of interacting drugs (digoxin, warfarin, antiarrhythmics)
- Inadequate monitoring frequency (must be at least every 6 months) 1
- Using drop counter infusion sets for IV administration (causes 30% underdosing) 2
- Administering concentrated solutions (>2 mg/mL) peripherally (causes phlebitis) 2
When to Consult Specialists 4
- Cardiology/Electrophysiology: For ICD consideration, complex arrhythmias, or when amiodarone fails
- Endocrinology: For thyroid dysfunction management
- Pulmonology: For suspected pulmonary toxicity
- Hepatology: For persistent transaminase elevation